{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:36:01Z","timestamp":1792035361790,"version":"4.4.0"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002003"],"award-info":[{"award-number":["UL1TR002003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1UM1AI104681-01"],"award-info":[{"award-number":["1UM1AI104681-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,1,27]]},"abstract":"<jats:p>\n            The\n            <jats:italic>ex vivo<\/jats:italic>\n            bactericidal activity and pharmacodynamics of fosfomycin in urine were evaluated in 18 healthy subjects. Subjects received 3\u2009g every other day (QOD) for 3 doses and then every day (QD) for 7 doses or vice versa. Serial urine samples were collected before and up to 24\u2009h after dosing on days 1 and 5. Eight bacterial strains with various genotypic and phenotypic susceptibilities to fosfomycin were used for all experiments (5\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            , 2\n            <jats:named-content content-type=\"genus-species\">Klebsiella pneumoniae<\/jats:named-content>\n            , and 1\n            <jats:named-content content-type=\"genus-species\">Proteus mirabilis<\/jats:named-content>\n            ).\n          <\/jats:p>","DOI":"10.1128\/aac.02102-19","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T11:09:09Z","timestamp":1574248149000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["<i>Ex Vivo<\/i>\n            Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-8400","authenticated-orcid":false,"given":"E.","family":"Wenzler","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Meyer","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C.","family":"Bleasdale","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sikka","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7646-0594","authenticated-orcid":false,"given":"K. L.","family":"Bunnell","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Finnemeyer","sequence":"additional","affiliation":[{"name":"Harvard TH Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Harvard TH Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. H.","family":"Danziger","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA"},{"name":"College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Rodvold","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA"},{"name":"College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_3_3_2","volume-title":"Monurol (fosfomycin tromethamine) [package insert]","author":"Forest Pharmeceuticals, Inc","year":"2007","unstructured":"Forest Pharmeceuticals, Inc. 2007. Monurol (fosfomycin tromethamine) [package insert]. Forest Pharmaceuticals, Inc., St. Louis, MO. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050717s005lbl.pdf. Accessed 11 May 2015."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-15"},{"key":"e_1_3_3_5_2","volume-title":"Trend of antimicrobial consumption by country","author":"European Center for Disease Prevention and Control","year":"2018","unstructured":"European Center for Disease Prevention and Control. 2018. Trend of antimicrobial consumption by country. European Center for Disease Prevention and Control, Solna, Sweden. https:\/\/ecdc.europa.eu\/en\/antimicrobial-consumption\/database\/trend-country. Accessed 5 August 2018."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2018.1500110"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936119858883"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.06.008"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004157"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ436"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000472872"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.039"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00464-18"},{"key":"e_1_3_3_14_2","volume-title":"Performance standards for antimicrobial susceptibility testing: approved 27th ed","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. Performance standards for antimicrobial susceptibility testing: approved 27th ed. Document M100-S27. CLSI, Wayne, PA."},{"key":"e_1_3_3_15_2","volume-title":"Subcommittee on antimicrobial susceptibility test meeting","author":"NCCLS","year":"1998","unstructured":"NCCLS. 1998. Subcommittee on antimicrobial susceptibility test meeting. NCCLS, Wayne, PA."},{"key":"e_1_3_3_16_2","volume-title":"Performance standards for antimicrobial susceptibility testing: approved 28th ed","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Performance standards for antimicrobial susceptibility testing: approved 28th ed. Document M100-S28. CLSI, Wayne, PA."},{"key":"e_1_3_3_17_2","volume-title":"Performance standards for antimicrobial susceptibility testing: approved 28th ed","author":"CLSI","year":"2019","unstructured":"CLSI. 2019. Performance standards for antimicrobial susceptibility testing: approved 28th ed. Document M100-S29. CLSI, Wayne, PA."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.07.018"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1659"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00477-06"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(98)00014-4"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.12.3789-3794.2003"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx441"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00775-17"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz181"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01133-08"},{"key":"e_1_3_3_27_2","first-page":"66","article-title":"Fosfomycin for urinary tract infections","volume":"39","year":"1997","unstructured":". 1997. Fosfomycin for urinary tract infections. Med Lett Drugs Ther 39:66\u201368.","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3627"},{"key":"e_1_3_3_29_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201310th ed","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201310th ed. M07-A10. CLSI, Wayne, PA."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/cmb.2012.0021"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.11.011"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.09.013"},{"key":"e_1_3_3_33_2","first-page":"466","volume-title":"Antibiotics and laboratory medicine","author":"Edberg S","year":"1986","unstructured":"Edberg S. 1986. The measurement of antibiotics in human body fluids: techniques and significance, p 466\u2013467. In Lorian V (ed), Antibiotics and laboratory medicine. The Williams & Wilkins Co., Baltimore, MD."},{"key":"e_1_3_3_34_2","volume-title":"Methods for determining bactericidal activity of antimicrobial agents: approved guideline: document M26-A","author":"CLSI","year":"1999","unstructured":"CLSI. 1999. Methods for determining bactericidal activity of antimicrobial agents: approved guideline: document M26-A. CLSI, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02102-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02102-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:07:06Z","timestamp":1645484826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02102-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,27]]}},"alternative-id":["10.1128\/AAC.02102-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02102-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"2019-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02102-19"}}